CRISPR-Cas9-guided amplification-free genomic diagnosis for familial hypercholesterolemia using nanopore sequencing
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0297231 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Sijia Xu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Nanopore Sequencing, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Familial hypercholesterolemia is an inherited disorder that remains underdiagnosed. Conventional genetic testing methods such as next-generation sequencing (NGS) or target PCR are based on the amplification process. Due to the efficiency limits of polymerase and ligase enzymes, these methods usually target short regions and do not detect large mutations straightforwardly. This study combined the long-read nanopore sequencing and CRISPR-Cas9 system to sequence the target DNA molecules without amplification. We originally designed and optimized the CRISPR-RNA panel to target the low-density lipoprotein receptor gene ( LDLR ) and proprotein convertase subtilisin/kexin type 9 gene ( PCSK9 ) from human genomic DNA followed by nanopore sequencing. The average coverages for LDLR and PCSK9 were 106× and 420×, versus 1.2× for the background genome. Among them, continuous reads were 52x and 307x, respectively, and spanned the entire length of LDLR and PCSK9 . We identified pathogenic mutations in both coding and splicing donor regions in LDLR . We also detected an 11,029 bp large deletion in another case. Furthermore, using continuous long reads generated from the benchmark experiment, we demonstrated how a false-positive 670 bp deletion caused by PCR amplification errors was easily eliminated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier, Tokyo University, Tokyo, Japan.
ORCID-Profile: Takahiro Horie, Koji Hasegawa, Takeshi Kimura, Koh Ono
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Xu, S., Shiomi, H., Yamashita, Y., Koyama, S., Horie, T., Baba, O., Kimura, M., Nakashima, Y., Sowa, N., Hasegawa, K., Suzuki, A., Suzuki, Y., Kimura, T., & Ono, K. (2024). CRISPR-Cas9-guided amplification-free genomic diagnosis for familial hypercholesterolemia using nanopore sequencing. PLOS ONE. https://doi.org/10.1371/journal.pone.0297231
Vancouver
Xu S, Shiomi H, Yamashita Y, Koyama S, Horie T, Baba O, et al. CRISPR-Cas9-guided amplification-free genomic diagnosis for familial hypercholesterolemia using nanopore sequencing. PLOS ONE. 2024. doi:10.1371/journal.pone.0297231
BibTeX
@article{Xu2024,
author = {Xu, Sijia and Shiomi, Hiroki and Yamashita, Yugo and Koyama, Satoshi and Horie, Takahiro and Baba, Osamu and Kimura, Masahiro and Nakashima, Yasuhiro and Sowa, Naoya and Hasegawa, Koji and Suzuki, Ayako and Suzuki, Yutaka and Kimura, Takeshi and Ono, Koh},
title = {CRISPR-Cas9-guided amplification-free genomic diagnosis for familial hypercholesterolemia using nanopore sequencing},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0297231}
}
EUVIMED